British National Formulary October 2024 Update
This update contains 11 significant changes, 2 dose changes and 3 new monographs.
Significant Changes:
- Borderline substances: enteral (tube) feeds have been re-organised in a new section called Enteral nutrition.
- Cholera vaccines: updated guidance for immunisation.
- Epimax® ointment and Epimax® paraffin-free ointment: reports of ocular surface toxicity and ocular chemical injury [MHRA/CHM advice] (advice in emollient creams and ointments, paraffin-containing and emollient creams and ointments, hydrogenated castor oil-containing).
- Human papillomavirus vaccine: updated guidance for immunisation.
- Immunisation schedule: updated guidance.
- Poisoning, emergency treatment: updated guidance for paracetamol overdose.
- Posaconazole: important safety information added to highlight that tablets and oral suspension are not directly interchangeable.
- Sacubitril with valsartan: update to dose expression.
- Sodium valproate: new precautionary advice for male patients [MHRA/CHM advice].
- Status epilepticus: updated guidance for management.
- Valproic acid: new precautionary advice for male patients [MHRA/CHM advice].
Dose Changes:
- Human papillomavirus vaccine [update to dosing].
- Levonorgestrel [update to indications and dose for intra-uterine devices].
New Monographs:
- Eladynos® [abaloparatide].
- Emollient creams and ointments, hydrogenated castor oil-containing.
- Pylera® [bismuth potassium with metronidazole and tetracycline hydrochloride].